Jay Dominguez, MD
Nephrology · Bradenton, FLNPI 1356845333
Payments from drug & device makers
Across 41 payments — averaging $23.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$153
- Calliditas Therapeutics US Inc.$135
- Ablative Solutions, Inc.$111
- Boehringer Ingelheim$105
- Otsuka America Pharmaceutical, Inc.$100
- Novartis$99
- plus $273 from 6 others
What the payments were for
- Food & beverage$975100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 7 | $153 |
| Calliditas Therapeutics US Inc. | 7 | $135 |
| Ablative Solutions, Inc. | 1 | $111 |
| Boehringer Ingelheim | 5 | $105 |
| Otsuka America Pharmaceutical, Inc. | 6 | $100 |
| Novartis | 4 | $99 |
| Baxter Healthcare | 1 | $85 |
| Aurinia Pharma U.S., Inc. | 3 | $50 |
| Bayer | 3 | $47 |
| Travere Therapeutics, Inc. | 2 | $37 |
| Nuwellis, Inc. | 1 | $31 |
| Ardelyx, Inc. | 1 | $23 |
How this compares
$975 in reported general payments places this provider in the 35th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 26 | $38,760 |
| Bumetanide | 116 | $3,671 |
| Chlorthalidone | 73 | $1,241 |
| Potassium Chloride | 23 | $952 |
| Nifedipine ErNifedipine | 32 | $904 |
| Valsartan | 19 | $754 |
| Carvedilol | 57 | $496 |
| Lisinopril | 33 | $256 |
| Losartan Potassium | 33 | $222 |
| Hydralazine Hcl | 17 | $177 |
| Tamsulosin Hcl | 14 | $163 |
| Amlodipine Besylate | 40 | $161 |
| Furosemide | 21 | $157 |
| Torsemide | 12 | $154 |
| Spironolactone | 19 | $86 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Bradenton
- Hakan TokaBradenton$1.2M
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
- Edouard MartinLauderdale Lakes$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.